KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Change in Receivables (2017 - 2025)

Historic Change in Receivables for BeOne Medicines (ONC) over the last 9 years, with Q3 2025 value amounting to $93.9 million.

  • BeOne Medicines' Change in Receivables rose 21467.77% to $93.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $293.0 million, marking a year-over-year increase of 1788.61%. This contributed to the annual value of $329.4 million for FY2024, which is 7495.09% up from last year.
  • According to the latest figures from Q3 2025, BeOne Medicines' Change in Receivables is $93.9 million, which was up 21467.77% from $41.5 million recorded in Q2 2025.
  • In the past 5 years, BeOne Medicines' Change in Receivables ranged from a high of $353.8 million in Q4 2021 and a low of -$292.6 million during Q1 2022
  • Moreover, its 5-year median value for Change in Receivables was $31.9 million (2025), whereas its average is $42.3 million.
  • Per our database at Business Quant, BeOne Medicines' Change in Receivables surged by 26396343.28% in 2021 and then tumbled by 133670.1% in 2022.
  • BeOne Medicines' Change in Receivables (Quarter) stood at $353.8 million in 2021, then crashed by 105.48% to -$19.4 million in 2022, then soared by 330.96% to $44.8 million in 2023, then surged by 180.61% to $125.7 million in 2024, then dropped by 25.28% to $93.9 million in 2025.
  • Its Change in Receivables was $93.9 million in Q3 2025, compared to $41.5 million in Q2 2025 and $31.9 million in Q1 2025.